Skip to main content

Table 2 Neoadjuvant chemotherapy and pathological characteristics in the LG and OG groups before and after PSM

From: Laparoscopic versus open gastrectomy for locally advanced gastric cancer after neoadjuvant chemotherapy: a comprehensive contrastive analysis with propensity score matching

Characteristics

Before PSM

After PSM

LG group [n = 80 (%)]

OG group [n = 68 (%)]

Χ2

p-value

LG group [n = 55 (%)]

OG group [n = 55 (%)]

Χ2

p-value

NC regimen

  

 − 

0.629

  

 − 

0.285

 FOLFOX

41 (51.3)

40 (58.8)

  

25 (45.5)

35 (63.6)

  

 SOX

31 (38.8)

24 (35.3)

  

25 (45.5)

17 (30.9)

  

 XELOX

4 (5.0)

3 (4.4)

  

2 (3.6)

2 (3.6)

  

 FLOT

4 (5.0)

1 (1.5)

  

3 (5.5)

1 (1.8)

  

Cycle of NC

  

3.611

0.164

  

2.334

0.311

 ≤ 2

34 (42.5)

39 (57.4)

  

25 (45.5)

33 (60.0)

  

 3

22 (27.5)

16 (23.5)

  

15 (27.3)

11 (20.0)

  

 ≥ 4

24 (30.0)

13 (19.1)

  

15 (27.3)

11 (20.0)

  

Clinical response of RECISTa

  

 − 

0.748

  

 − 

0.504

 CR

2 (2.5)

1 (1.5)

  

2 (3.6)

1 (1.8)

  

 PR

35 (43.8)

25 (36.8)

  

27 (49.1)

21 (38.2)

  

 SD

38 (47.5)

38 (55.9)

  

25 (45.5)

30 (54.5)

  

 PD

5 (6.3)

4 (5.9)

  

1 (1.8)

3 (5.5)

  

Tumor regression gradeb

  

 − 

0.357

  

 − 

0.264

 0

4 (5.0)

1 (1.5)

  

4 (7.3)

1 (1.8)

  

 1

6 (7.5)

9 (13.2)

  

5 (9.1)

8 (14.5)

  

 2

26 (32.5)

17 (25)

  

20 (36.4)

14 (25.5)

  

 3

44 (55.0)

41 (60.3)

  

26 (47.3)

32 (58.2)

  

ypT stagec

  

 − 

0.221

  

 − 

0.266

 0

4 (5.0)

1 (1.5)

  

4 (7.3)

1 (1.8)

  

 1

6 (7.5)

9 (13.2)

  

4 (7.3)

8 (14.5)

  

 2

9 (11.3)

7 (10.3)

  

7 (12.7)

6 (10.9)

  

 3

31 (38.8)

36 (52.9)

  

20 (36.4)

28 (50.9)

  

 4a

26 (32.5)

13 (19.1)

  

17 (30.9)

10 (18.2)

  

 4b

4 (5.0)

2 (2.9)

  

3 (5.5)

2 (3.6)

  

ypN stagec

  

2.679

0.444

  

3.728

0.292

 0

27 (33.8)

18 (26.5)

  

21 (38.2)

17 (30.9)

  

 1

14 (17.5)

12 (17.6)

  

10 (18.2)

9 (16.4)

  

 2

19 (23.8)

13 (19.1)

  

12 (21.8)

8 (14.5)

  

 3

20 (25.0)

25 (36.8)

  

12 (21.8)

21 (38.2)

  

ypTNM stagec

  

 − 

0.876

  

 − 

0.478

 PCR

4 (5.0)

1 (1.5)

  

4 (7.3)

1 (1.8)

  

 I

10 (12.5)

9 (13.2)

  

9 (16.4)

9 (16.4)

  

 II

22 (27.5)

19 (27.9)

  

14 (25.5)

16 (29.1)

  

 III

39 (48.8)

34 (50.0)

  

27 (49.1)

25 (45.5)

  

 IV

5 (6.3)

5 (7.4)

  

1 (1.8)

4 (7.3)

  

Histological type

  

0.225

0.635

  

0.170

0.680

 Differentiated

23 (28.8)

22 (32.4)

  

16 (29.1)

18 (32.7)

  

 Undifferentiated

57 (71.3)

46 (67.6)

  

39 (70.9)

37 (67.3)

  

Lymph-vascular invasion

  

1.075

0.300

  

0.176

0.675

 Yes

50 (62.5)

48 (70.6)

  

38 (69.1)

40 (72.7)

  

 No

30 (37.5)

20 (29.4)

  

17 (30.9)

15 (27.3)

  

Nerve invasion

  

0.979

0.322

  

1.803

0.179

 Yes

43 (53.8)

31 (45.6)

  

34 (61.8)

27 (49.1)

  

 No

37 (46.3)

37 (54.4)

  

21 (38.2)

28 (50.9)

  

Postoperative adjuvant chemotherapy

  

0.103

0.748

  

0.064

0.801

 Yes

63 (78.8)

55 (80.9)

  

45 (81.8)

46 (83.6)

  

 No

17 (21.3)

13 (19.1)

  

10 (18.2)

9 (16.4)

  
  1. PSM propensity score matching, LG laparoscopic gastrectomy, OG open gastrectomy, NC neoadjuvant chemotherapy, FOLFOX oxaliplatin, leucovorin, and 5-fluorouracil, SOX oxaliplatin and TS-1, XELOX oxaliplatin and capecitabine, FLOT docetaxel, oxaliplatin, leucovorin, and fluorouracil, RECIST Response Evaluation Criteria in Solid Tumors, CR complete response, PR partial response, SD stable disease, PD progressed disease, PCR pathological complete response
  2. aAccording to the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1)
  3. bAccording to the AJCC standard
  4. cAccording to the 8th edition of the American Joint Committee on Cancer Cancer Staging Manual
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us